 |
|
|
|
|
Product Details:
Payment & Shipping Terms:
|
| Name: | Eribulin Mesylate | Cas: | 441045-17-6 |
|---|---|---|---|
| Mf: | C8H17NO2 | Purity: | 99% |
| Appearance: | White Powder | Package: | 1kg/bag Or 25kgs/drum |
| High Light: | API 99% Eribulin Mesylate,441045-17-6 Chemical Raw Material,C8H17NO2 Eribulin Mesylate |
||
API 99%Min Eribulin Mesylate CAS 441045-17-6 Raw Material Powder Anticancer Eribulin Mesylate
Introduction
The U.S. FDA approved eribulin mesylate (also referred to as E7389) in November 2010 for the treatment of metastatic breast cancer (MBC) for patients who previously received at least two chemotherapeutic regimens for late-stage disease. Eribulin is a synthetic analog of the marine natural product halichondrin B, which is isolated from the sea sponge Halichondria okadai. Eribulin retains most of the structural elements that constitute the right hand side of halichondrin B; structure-activity relationship (SAR) studies suggested that the antitumor activity of halichondrin B resides in that part of the molecule . Eribulin is a microtubule inhibitor that binds close to the vinca-binding site of tubulin. Unlike most tubulin inhibitors like taxanes, epothilones, and vinca alkaloids that inhibit microtubule dynamic instability by changing tubulin addition and loss parameters, eribulin's effects on dynamic instability are novel in that eribulin inhibits the growth phase of microtubules without affecting the shortening phase by binding to microtubule plus ends.
| Product Name: | Eribulin Mesylate |
| Synonyms: | Halaven;Eribulin mesylate Halaven;Eribulin Mesilate |
| CAS: | 441045-17-6 |
| MF: | C40H59NO11.CH4O3S |
| MW: | 729.89656 |
| Product Categories: | API |
| Molecular Structure: |
Application
A methanesulfonate salt obtained by reaction of eribulin with one equivalent of methanesulfonic acid. A fully synthetic macrocyclic ketone analogue of marine sponge natural products. Inhibits growth phase of microtubules via tubulin-based antimitotic mecha ism, which leads to G2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage.
| Adenosine | AR | 58-61-7 | ≥99% |
| Uridine | UR | 58-96-8 | ≥99% |
| Cytidine | CR | 65-46-3 | ≥99% |
| Xanthosine 5-monophosphate disodium salt | XMP- Na2 | 25899-70-1 | ≥98% |
| Inosine-5'-monophosphate disodium salt octahydrate | IMP- Na2 | 20813-76-7 | ≥98% |
| Adenosine 5′-monophosphate disodium salt | AMP- Na2 | 4578-31-8 | ≥98% |
| Adenosine 5'-Monophosphatesodiumsalt | AMP- Na | .13474-03-8 | ≥98% |
| 5-Adenylic acid | AMP | 61-19-8 | ≥98% |
| Adenosine 3',5'-cyclic monophosphate | Cyclic AMP,CAMP | 60-92-4 | ≥97% |
| Uridine 5-monophosphate, disodium salt | UMP- Na2 | 3387-36-8 | ≥98% |
| Uridine 5'-monophosphate | UMP | 58-97-9 | ≥98% |
| Cytidine 5''-monophosphate disodium salt | CMP- Na2 | .6757-06-8 | ≥98% |
| Cytidine 5′-monophosphate | CMP | 63-37-6 | ≥98% |
| Citicoline sodium | CDPC-Na | 33818-15-4 | ≥98% |
| uridine 5'-diphosphate disodium salt | UDP-Na2 | 27821-45-0 | ≥95% |
| IDP-K2 | ≥90% | ||
| Inosine-5'-diphosphoric acid disodium salt | IDP-Na2 | 54735-61-4 | ≥90% |
| Cytidine 5'-Diphosphate Trisodium Salt Hydrate | CDP-Na3 | 34393-59-4 | ≥90% |
| Cytidine-5'-diphosphate disodium salt | CDP-Na2 | 54394-90-0 | ≥90% |
| Adenosine 5'-diphosphate dipotassiuM salt | ADP-K2 | 114702-55-5 | ≥95% |
| Adenosine-5'-diphosphate, MonopotassiuM salt | ADP-K | 72696-48-1 | ≥95% |
| Adenosine-5-diphosphate disodium salt | ADP-Na2 | 16178-48-6 | ≥95% |
| Adenosine 5''-diphosphate sodium salt | ADP-Na | 20398-34-9 | ≥95% |
| Adenosine 5''-diphosphate | ADP | 58-64-0 | ≥95% |
| Uridine 5'-triphosphate disodium salt | UTP-Na3 | 19817-92-6 | ≥90% |
| Uridine-5'-triphosphoric acid trisodium salt | UTP-Na2 | 285978-18-9 | ≥90% |
| CTP-Na3 | ≥95% | ||
| Cytidine 5′-triphosphate disodium salt | CTP-Na2 | 36051-68-0 | ≥95% |
| Adenosine 5'-triphosphate disodium salt | ATP-Na2 | 987-65-5 | ≥95% |
| Adenosin-5'-triphosphat | ATP | 56-65-5 |
Contact Person: July
Tel: 25838890
